The round was led by iSelect Fund with participation from existing investors Agilent Technologies, Alexandria Venture Investments, and Keshif Ventures.
The company intends to use the funds to advance its proprietary enzymatic DNA synthesis technology to power DNA-based products in synthetic biology.
Led by Michael J. Kamdar, President and CEO, Molecular Assemblies develops an enzymatic DNA synthesis technology designed to power DNA-based products. Enzymatic DNA synthesis can write long, pure DNA, which is required to free the potential of synthetic biology applications, such as personalized medicines (including CAR-T cell therapies and CRISPR gene editing), and advanced agricultural and industrial products, through gene development and DNA-based data storage.
Scientists at Molecular Assemblies have pioneered a two-step enzymatic DNA synthesis process that can deliver pure, sequence-specific DNA on demand, without a template, and can scale to longer DNA sequences. This proprietary process uses aqueous, non-toxic reagents and requires minimal post-synthesis purification and processing.
FinSMEs
01/10/2019